Radiogenomics: Using genetics to identify cancer patients at risk for development of adverse effects following radiotherapy

Sarah L. Kerns, Harry Ostrer, Barry S. Rosenstein

Research output: Contribution to journalReview article

60 Scopus citations

Abstract

Normal-tissue adverse effects following radiotherapy are common and signifi - cantly affect quality of life. These effects cannot be accounted for by dosimetric, treatment, or demographic factors alone, and evidence suggests that common genetic variants are associated with radiotherapy adverse effects. The field of radiogenomics has evolved to identify such genetic risk factors. Radiogenomics has two goals: (i) to develop an assay to predict which patients with cancer are most likely to develop radiation injuries resulting from radiotherapy, and (ii) to obtain information about the molecular pathways responsible for radiation-induced normal-tissue toxicities. This review summarizes the history of the field and current research.

Original languageEnglish (US)
Pages (from-to)155-165
Number of pages11
JournalCancer discovery
Volume4
Issue number2
DOIs
StatePublished - Feb 2014

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Radiogenomics: Using genetics to identify cancer patients at risk for development of adverse effects following radiotherapy'. Together they form a unique fingerprint.

  • Cite this